Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Tango Therapeutics Inc shares valued at $4,846,575 were sold by Third Rock Ventures IV, L.P. on Oct 23 ’25. At $10.15 per share, Third Rock Ventures IV, L.P. sold 477,401 shares. The insider’s holdings dropped to 13,386,574 shares worth approximately $167.47 million following the completion of this transaction.
Also, Third Rock Ventures IV, L.P. purchased 477,401 shares, netting a total of over 3,594,830 in proceeds.
Before that, Third Rock Ventures IV, L.P. had sold 500,000 shares from its account. In a trade valued at $4,008,500, the 10% Owner traded Tango Therapeutics Inc shares for $8.02 each. Upon closing the transaction, the insider’s holdings decreased to 500,000 shares, worth approximately $173.44 million.
As published in their initiating research note from Wolfe Research on November 18, 2025, Tango Therapeutics Inc [TNGX] has been a Peer perform. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid August. As of July 17, 2024, Jefferies has initiated its “Buy” rating for TNGX. Earlier on April 04, 2024, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for TNGX stock.
Analyzing TNGX Stock Performance
The stock’s lowest price that day was $12.18, but it reached a high of $12.7 in the same session. During the last five days, there has been a surge of approximately 19.83%. Over the course of the year, Tango Therapeutics Inc shares have jumped approximately 338.95%.
Is Tango Therapeutics Inc subject to short interest?
Stocks of Tango Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 6.72 million shares to 39.97 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 33.25 million shares. A jump of 16.82% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 15.73 of the overall float, the days-to-cover ratio (short ratio) jumped to 15.73.
Which companies own the most shares of Tango Therapeutics Inc (TNGX)?
In terms of Tango Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 14 in the next 12 months, up nearly 11.91% from the previous closing price of $12.51. Analysts anticipate Tango Therapeutics Inc stock to reach 15 by 2026, with the lowest price target being 12. In spite of this, 3 analysts ranked Tango Therapeutics Inc stock as Buy at the end of 2026. On February 12, 2024, Piper Sandler assigned a price target of “an Overweight” to the stock and initiated coverage with a $18.
